The startup, which is developing treatments for Alzheimer's disease, received the money in a Pfizer-led round that also included Takeda's corporate venturing unit.

Pharmaceutical company Pfizer has led a $15m series A round for US-based Alzheimer’s disease treatment developer Cortexyme. Japan-based pharmaceutical firm Takeda Pharmaceutical Company also took part in the round, investing through its Takeda Ventures unit, as did existing investors including venture capital firm Dolby Family Ventures. Cortexyme is working on treatments for Alzheimer’s and other…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.